The phosphatidylinositol 3-kinase (PI3K)-AKT and RAS-MAPK pathways are deregulated in a wide range of human cancers by gain or loss of function in several of their components. Our purpose has been to identify genetic alterations in members of these pathways in prostate cancer. A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed. PIK3CA, KRAS, BRAF and AKT1 mutations were analyzed by direct sequencing, and BRAF also by pyrosequencing. PIK3CA quantitative mRNA expression and fluorescence in situ hybridization (FISH) gains were tested in 25 and 32 prostate tumors from both groups (G1 and G2), respectively. Immunohistochemistry for pAKT was performed in 55 prostate tumors. Of 25 prostate tumors, 10 (40%) had PIK3CA mRNA overexpression that was statistically associated with Gleason score Z7 (P ¼ 0.018). PIK3CA copy gain was detected in 9 of 32 (28%) prostate tumors. Of 20 bladder tumors, 3 (15%) displayed mutations in PIK3CA, KRAS and AKT1, the corresponding prostate tumors being wt. We also detected a previously not reported PIK3CA polymorphism (IVS9 þ 91) in two prostate tumors. In all, 56% of prostate tumors overexpressed pAKT. There is a statistical association (Po0.0001) of strong pAKT immunostaining with high Gleason score, and with PIK3CA alterations (mRNA overexpression and/or FISH gains). PIK3CA gene is deregulated by mRNA overexpression and DNA gain in B40 and 28% of prostate tumors, respectively. High-grade prostate tumors are associated with PIK3CA mRNA overexpression, but not with FISH status. PIK3CA, BRAF, KRAS and AKT1 mutations are very infrequent events in prostate tumors. However, PI3K signaling pathway is activated by PIK3CA FISH gain and/or mRNA overexpression, leading to an increased pAKT protein expression.
amplified in different human tumor types. 2, 6 The RAS-MAPK and PI3K-AKT pathways are strongly interconnected and have a central role in tumorigenesis. RAS is activated by growth factors and hormone signaling, binding to RAF proteins (also named MAPKKKs). The activation of RAF proteins causes the subsequent phosphorylation and activation of MEK1 and 2 (MAPKKs)/ERK1 and 2 (MAPKs). 7 The major downstream target of RAS is MAPKs, but it is also known to activate other targets like PI3K. 8 Furthermore, it has also been published 9 that AKT can inhibit the Raf-MEK-ERK pathway, through the inhibition of RAF phosphorylation. 9 The PI3K signaling pathway can be activated by two main different mechanisms: activating mutation and amplification. More than 80% of mutations are clustered in exons 9 and 20 (helical and kinase domain) with three hot spot mutations, E542K, E545K and H1047R. 6 To date, only three studies have reported PIK3CA alterations in prostate cancer. [10] [11] [12] Two of them described PIK3CA amplification, and only the most recent study by Sun et al 12 found for the first time PIK3CA mutations in B3% of prostate tumors. Data from the 'Catalogue of Somatic Mutations in Cancer' (www.sanger.ac.uk) reported a mutation frequency of 2%.
KRAS mutations have been described in up to 13% of prostate cancers, with differences in the prevalence rates between Japanese and American men. [13] [14] [15] [16] Two reports have been published about BRAF mutations in prostate tumors, but only Cho et al 16 described 10% of mutations in their Asian population. Most of BRAF mutations in human cancer consist in the missense mutation V600E 17 (see http://www.sanger.ac.uk/ genetics/CGP/cosmic/). It has been reported that BRAF mutations occur in many tumor types in which KRAS is frequently mutated. 16, 18 To date, only one article has reported AKT1 mutations in prostate cancer. Boormans et al 19 described the E17K change in 1 of 92 prostate tumors. The mutated sample presented a pAKT overexpression, suggesting activation of the AKT pathway. 19 In summary, the constitutive activation of the PIK3-AKT and RAS-RAF pathways can result from different and/or complementary aberrant events, including constitutive active mutation, gene amplification, overexpression or loss of function. Although other authors have studied different components of the PI3K-AKT and RAS-RAF pathways, this is the first article in which various members of both pathways have been analyzed together in the same set of prostate samples in order to test their involvement in prostate cancer.
Materials and methods

Tumor Samples and Patients
A total of 102 cases of prostate cancer from the files of the Department of Pathology at the Hospital del Mar in Barcelona, Spain, are the subject of this report. All cases were collected between 1997 and 2008. None of the patients received previous chemotherapy or hormone therapy. In all, 72 cases were formalin-fixed, paraffin-embedded (FFPE) samples, 30 were frozen tissues, and none of them were matched. From these 72 cases, 65 were biopsy or prostatectomy specimens from patients with only prostate cancer (group G1; 7 were needle biopsies), and 23 were from patients who, in addition to prostate cancer, had another independent tumor in the bladder (group G2; 18 from cystoprostatectomy specimens and 5 from patients with radical prostatectomy and transurethral bladder biopsy). Stage and grade of the 23 bladder tumors from group 2 (G2) are shown in Table 1 . In 6 patients from G2 with high grade and stage bladder cancer, we selected a previous bladder tumor biopsy with lower grade and stage for comparing molecular changes in PIK3CA in both bladder tumor samples. According to the Gleason grade, the 102 prostate samples were: 36 tumors with Gleason ¼ 6, 52 with Gleason ¼ 7 and 14 with Gleason Z8.
Mutational Analysis (PCR Reaction and Direct Sequencing)
In adequate tumor areas, manual microdissection and DNA extraction from FFPE and frozen tissues was performed as previously described. 20 In this study, we focused on analyzing the hot spot mutation codons and surrounding exonic regions of PIK3CA, KRAS, BRAF and AKT1 in 81 prostate tumor samples from group G1 and 23 from G2. In group G2, we also performed mutational analysis of 20 corresponding bladder tumors. In addition, we also analyzed the 5 0 upstream region of exon 20 of PIK3CA in 56 samples (50 from group G1 and 6 from G2).
As previous studies have reported the presence of a pseudogene extending from exons 9 to 13 for PIK3CA, we designed specific primers for exon 9 in order to amplify only the standard gene sequence of PIK3CA.
21-23
The primer sequences, annealing temperature, PCR product size, exons and hot spot codons analyzed are shown in Table 2 .
PCR reactions, product purification (Qiagen, Crawley, UK) and mutational analysis were performed as previously described with the Big Dye Terminator Kit v.3.1 (ABIPRISM 377, PerkinElmer Applied Biosystems). 20 Each PCR product was sequenced in both forward and reverse directions. In all cases where a change was identified in the first PCR reaction, an independent PCR amplification and sequencing experiment was performed.
BRAF Pyrosequencing Assay
A total of 54 samples were analyzed by pyrosequencing and direct sequencing. PCR amplification primers and annealing temperatures are shown in PIK3CA alterations in prostate tumors Table 2 . PCR reactions were performed in a 25 ml volume using 10-50 ng of DNA. The products underwent electrophoresis in an agarose gel to confirm successful amplification of the 140 bp PCR product. The PCR products were sequenced by the Pyrosequencing PSQ96 HS System (Biotage AB) following the manufacturer's instructions.
Total RNA Extraction and Quantitative Real-Time RT-PCR Analysis
Total RNA was extracted from 25 frozen prostate tumor samples (Table 3) with Ultraspec and RNeasy Mini kit (Qiagen, Chatsworth, CA, USA) from 10 to 15 sections of 10 mm. All samples contained a TaG2  77  4+3  T4G3  WT  WT  WT  T1G2  78  5+4  T2G3  WT  Not done  --79  3+3  T3aG3  WT  E545K (PIK3CA)  --80  3+4  T1G3  WT  WT  --81  3+4  T2G3 WT WT --
The shaded words represent the specific mutation and the gene abbreviation. 
minimum of 70% of tumor cells. We also selected four normal samples as controls. Total RNA purity and quality were assessed with the NanoDrops ND-100 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). PIK3CA mRNA expression was analyzed by quantitative real-time PCR in the 25 samples, on the ABI PRISM 7000 Sequence Detection System using the TaqMans Gene Expression Assays probe and primer mix (Applied Biosystems) according to the manufacturer's specifications. The Assay Identification number was HS00180679_m1. Human B2M was used as endogenous control. The samples were run in triplicate and the mean value was calculated for each case. Non-carcinomatous prostate tissues (4 cases/run) were used to normalize the data using the DDCt method. Values 41.9 reflect an overexpression of PIK3CA mRNA.
PIK3CA Fluorescence In Situ Hybridization (FISH) Analysis
FISH analysis was carried out on FFPE tissues in 32 cases (Table 3) . PIK3CA probe was prepared from bacterial artificial chromosome (BAC) clones (pooled RP11-680J18 and RP11-386L21) selected from the CHORI BAC/PAC resource (http://bacpac. chori.org) and positioned to G-banded metaphase spreads via FISH. BAC DNA was labeled directly in SpectrumGreen-dUTPs (Abbott Molecular, Des Plaines IL, USA). Then, we made a mixture of PIK3CA probe with a commercial centromeric a-satellite probe specific for chromosome 3 (Abbott Molecular, Spectrum red), in which PIK3CA is located. Pretreated tissue sections and mixture of probes were co-denatured at 78 1C and hybridized overnight at 37 1C (Hybrite chamber; Abbot Molecular). After posthybridization washes, slides were counterstained with 4,6-diamino-2-phenylindole (DAPI) (Abbott Molecular).
Results were analyzed in a fluorescence microscope (Olympus, BX51) using the Cytovision software (Applied Imaging, Santa Clara, CA, USA). A minimum of 100 nuclei were scored by two different observers. We used adjacent normal tissues from five cases as controls, to establish the cutoff value (mean þ 3 s.d.) for polysomy (3 to 4 copies; 3.3%) and for monosomy (45%).
Immunohistochemistry of pAKT in Prostate Tumors
Immunohistochemical staining for pAKT was performed using the phospho-AKT (Ser473) antibody (Cell Signaling Technology, Beverly, MA, USA). A total of 55 samples were tested for pAKT expression (14 tumors with Gleason ¼ 6, 30 with Gleason ¼ 7 and 11 with Gleason Z8; Table 3 ). pAKT was detected in both cytoplasm and nucleus. The results were graded, considering separately cytoplasmic and nuclear immunostaining, as 0 (negative), 1 (weak), 2 (moderate; Figure 5a ), and 3 (strong; Figure 5b ). The score (histoscore) for each of them was the sum of the product of the staining intensity and corresponding tumor percentage (histoscore
. 24 For this study, the tumor score was obtained from the addition of the nuclear and cytoplasmic histoscores. A final tumor score 0-50 was considered negative or weak, between 50 and 100 moderate and 4100 was considered strong positivity.
Results
PIK3CA, KRAS and AKT1 Mutational Analysis
No mutations were detected in PIK3CA, KRAS or AKT1 in the prostate tumors from patients with only prostate cancer (G1) or in the tumors from patients with bladder and prostate cancer (G2). On the other hand, we identified a previously not reported polymorphism in intron 9 of PIK3CA (IVS9 þ 91) in two prostate tumors (one in each group, G1 and G2), generated by a transition C-T. The corresponding normal adjacent prostate tissue and normal seminal vesicle tissue (in the case from G1 group) and the matched muscle-invasive (T2G3) bladder tumor and normal bladder tissue (in the case from G2), were also analyzed. All of them presented the IVS9 þ 91, confirming the polymorphic nature of this change. Both prostate tumors harbored, in addition, the previously reported polymorphic change T1025T, 
which was also present in the normal tissue from the two cases and in the bladder tumor from one of them. There seems to be an association between the presence of polymorphisms IVS9 þ 91 and T1025T, because both were present at the same time and never occurred separately. As stated above, in the study of the matched bladder and prostate tumors from G2, none of the prostate tumors harbored any mutations. In the respective bladder tumors from this group, we detected three mutated samples (3 of 20, 15%), with mutations in PIK3CA, KRAS and AKT1 genes, respectively ( Figure 1 ). All mutations were found in hot spot codons: E545K in PIK3CA, G12V in KRAS and E17K in AKT1. None of the bladder tumors had mutations in BRAF. Previous papers on PIK3CA alterations in bladder cancer have reported from 13 to 25% of mutations in this gene, but with a higher prevalence in superficial than in deeply infiltrating bladder tumors. 25, 26 In our study, most of the bladder samples were high-grade and high-stage tumors (Table 1) . For this reason, we also investigated PIK3CA mutations in previous superficial bladder tumors in six patients from G2, also with negative results.
BRAF Mutational Analysis by Direct Sequencing and Pyrosequencing Technique
In order to confirm that no BRAF mutations were present, we not only performed direct sequencing but also pyrosequencing in prostate and bladder tumor samples. Different studies have found that pyrosequencing is a more sensitive and specific method than direct sequencing for detecting mutations. The limit for mutant allele detection ranges between 2.5 and 5% with the pyrosequencing technique, compared with the 10-20% obtained with direct sequencing. [27] [28] [29] As a positive control, we used a colon tumor harboring the V600E mutation, which was detected by both direct sequencing and pyrosequencing ( Figure 2 ). Direct sequencing was performed in all prostate tumors and in 17 of the bladder tumors from G2, and we did not detect any mutation. Pyrosequencing was performed in 39 
PIK3CA Quantitative mRNA Expression
The mRNA PIK3CA expression was investigated in 25 prostate tumors. From these 25 samples, 10 tumors were Gleason ¼ 6, 11 were Gleason ¼ 7 and 3 were Gleason Z8. The mRNA expression index ranged between 0.56 and 3.9. Based on the statistical analysis, the cutoff assumed for mRNA overexpression was 41.9. Of 25 prostate tumors, 10 (40%) showed PIK3CA overexpression, and all but one of them were Gleason Z7 (1 case was Gleason ¼ 6, 7 were Gleason ¼ 7 and 2 were Gleason ¼ 9; Figure 3) . Thus, PIK3CA mRNA overexpression was statistically associated with high-grade Gleason score in prostate tumors (Fisher's exact test, P-value ¼ 0.018). In 19 of these 25 samples, the mutation analysis was also performed with negative results.
PIK3CA FISH Analysis
From the 81 prostate tumors in which mutational study was done, we were able to perform FISH analysis in 32 samples. Of these 32 cases, 9 (28%) showed gain of PIK3CA gene because of chromosome 3 polysomy, being PIK3CA/centromere 3 ratio o1.5 ( Figure 4 ). All of these cases had 3 to 4 copies of chromosome 3 in 16-50% of cells. From these nine samples, three had Gleason ¼ 6 and six samples had Gleason ¼ 7. No statistical correlation was found between polysomy and Gleason score. From the ten cases in which we have information on PIK3CA by both FISH and qRT-PCR analysis, six cases showed concordant results (Table 4) . Two cases with wt FISH showed mRNA overexpression. In the two other tumors we found copy number gain but not mRNA overexpression, and thus other molecular mechanisms might be regulating PIK3CA mRNA expression in these cases.
Immunohistochemistry of pAKT and Association with PIK3CA Alterations
We could perform immunohistochemistry of pAKT in 55 prostate tumors (Figure 5a and b) . In 40 of them, the mutational analysis was available and showed negative results. The total (nucleus þ cytoplasm) histoscore of pAKT in the tumor samples ranged from 0 to 300. Considering strong expression, a histoscore 4100, there was a statistical correlation between high pAKT protein expression and the Gleason score (Po0.0001), as 1 of 14 Gleason ¼ 6 (7.1%), 12 of 32 Gleason ¼ 7 (37.5%) and 9 of 9 Gleason Z8 (100%) showed high pAKT levels. In addition, there was a correlation between high intensity of pAKT expression and PIK3CA overexpression (qRT-PCR) and/or amplification (FISH analysis) (Po0.0001). For this statistical analysis, we classified a sample as having a PIK3CA change when one or both techniques (FISH gains or mRNA overexpression) were positive (Table 4) .
Discussion
This paper is the first to analyze the combined impact of the activation of PI3K-AKT and RAS-RAF pathways, rather than their individual members, on prostate cancer. It is also the first to report PIK3CA alteration by mRNA overexpression in B40% of prostate cancer cases, in addition to PIK3CA copy number gain also in around 28% of tumors. PIK3CA and/or qRT-PCR were available and in which pAKT immunohistochemistry was performed mRNA overexpression and/or FISH gain are associated with high levels of pAKT protein, and PIK3CA mRNA overexpression is associated with high-grade Gleason score in prostate tumors (Fisher's exact test, P ¼ 0.040).
The lack of mutations in PIK3CA, AKT1, KRAS and BRAF in our series of prostate cancer indicates that mutations in these genes are not key elements in prostate cancer pathogenesis. These results are in concordance with previous published studies, most of them based on a smaller number of cases or not precisely defining the clinicopathological features of the samples. In our study we have selected a larger, well-defined group of patients. Moreover, to the best of our knowledge, this study is the first to investigate different molecules of the PI3K signaling pathway in the same subset of patients. Another new approach of our study is to compare patients harboring only a prostate tumor (G1) and those with both prostate and bladder cancer (G2). This is based on a previous study from our group 20 in which a higher frequency of mutations of FGFR3 was found in patients in whom prostate cancer occurred in association with tumors in bladder, skin and other tissues.
In several tumor types, alterations in different elements of PI3K-AKT and RAS-MAPK pathways are common events. 30, 31 The constitutive activation of the PI3K pathway can result from different and/or complementary aberrant events. At present, there are only three reports on PIK3CA alterations in prostate cancer. Edwards et al 10 found amplification of PIK3CA in 39% of hormone-sensitive tumors and 50% of hormone-independent tumors by CGH arrays; Muller et al 11 also reported the lack of PIK3CA mutations in 12 cases of prostate cancer. A recent study 12 has reported PIK3CA mutations in prostate tumors for the first time, although only in 1 of 40 cases, along with PIK3CA amplification in 13% of the cases. Our results are in agreement with these reports on the null or very low occurrence of mutations in PIK3CA. In addition, we have also found gene copy number gain in B28% of tumors, and for the first time we also report PIK3CA mRNA overexpression in a high proportion of prostate tumors.
We have not found KRAS or BRAF mutations. Discrepancies in the frequency of mutation of KRAS and BRAF have been reported for prostate cancer. KRAS mutations have been found in up to 8% of prostate tumors (see http://www.sanger.ac.uk/ genetics/CGP/cosmic/). [13] [14] [15] [16] The first study on BRAF alterations in prostate cancer 18 revealed no mutations in the prostate adenocarcinomas of 17 Caucasian patients (0/17). The second study, in Asian patients, found a frequency of BRAF and KRAS mutation of 10 and 7%, respectively. 16 Our series was made up of Caucasian patients and this could account for the lack of mutations in these genes. We confirmed this negative result for BRAF in a subset of cases by means of pyrosequencing.
The most recent reports on AKT suggest that only AKT1 isoform shows mutations in certain types of human cancer, in a low proportion of cases. 32 We did not detect AKT1 mutations in our samples, and in fact only a single case of prostate cancer with mutated AKT1 has been reported in the literature. 19 Thus, our results confirm that AKT1 mutations are very uncommon in prostate cancer, and that AKT may be activated through other mechanisms. Phosphorylation-activation of AKT could be the result of diverse alterations in different key genes of the PI3K-AKT pathway. In that sense, the only AKT1 mutated prostate tumor reported to date 19 showed pAKT overexpression. Some authors have shown that AKT is upregulated in prostate cancer compared with benign prostatic tissue (BPT), prostatic intraepithelial neoplasia (PIN) and primary tumors graded 2-5 according to Gleason. 33, 34 Interestingly, no change in the degree of AKT expression was detected in studies in which tumors had Gleason scores ranging from 6 to 10. 35, 36 On the other hand, the staining intensity for pAKT has been reported to be significantly greater in prostate tumors with high Gleason grade (Gleason 8-10) . [35] [36] [37] These reports are in concordance with the results of the present study, in which there was statistical correlation between pAKT expression and Gleason score Po0.0001. Finally, we have also found a statistical correlation between pAKT and PIK3CA mRNA overexpression and/or PIK3CA copy gain Po0.0001. Most of the cases analyzed with both techniques showed concordant results. Therefore, we can speculate that FISH gain could lead to an increase of PIK3CA mRNA expression and subsequent pAKT activation. On the other hand, it is also interesting to note that two cases with wt FISH showed mRNA overexpression and high levels of pAKT and two cases with FISH gain but not mRNA overexpression did not show high levels of pAKT intensity. Thus, other molecular mechanisms might be regulating PIK3CA mRNA expression in these cases.
Some of the patients in our study presented, in addition to prostate cancer, a simultaneous or previous urothelial neoplasm. Therefore, we have also performed the mutational study in the corresponding bladder tumors and we have found mutations in PIK3CA, KRAS and AKT1 in some cases, but not in the respective prostate tumors. Data from the literature reveal that independent bladder tumors harbor B13-25% of PIK3CA mutations. 25, 26 We found a lower percentage of mutations of this gene (5%) in the bladder tumors from patients with prostate cancer. This difference could be related to the fact that bladder tumors in patients with and without prostate cancer could progress through different pathways, but it could also be explained by differences in the bladder tumors included in our study. Most of the bladder tumors from G2 were muscle invasive, whereas PIK3CA mutations are more frequent in superficial tumors. 25, 26 To investigate whether the differences in the prevalence of PIK3CA mutations were because of the invasive nature of the G2 bladder tumors, we selected six of these cases in which a previous, superficial, lowgrade bladder tumor was available, and we did not find PIK3CA mutations in any of them. Interestingly, the only bladder tumor with mutated PIK3CA in our study was deeply invasive and high grade (T3G3).
The main goal of this study has been to comprehensively assess the PI3K-AKT and RAS-RAF signaling pathway status in prostate tumors with and without associated bladder cancer. This is the first work in which several different genes rather than individual genes in the pathways have been investigated in a large group of prostate tumors. According to our results, mRNA overexpression emerges as a new type of PIK3CA alteration in prostate tumors. A high proportion of prostate tumors are altered through PIK3CA mRNA overexpression and/or DNA gain, and mRNA overexpression is associated with high Gleason score (Z7), whereas copy number gain is not. Although PI3K and AKT have been suggested to be promising molecular targets in the management of prostate cancer, 36, 38 PIK3CA, BRAF, KRAS and AKT1 mutations represent very infrequent events in this tumor. We have shown, in addition, that PIK3CA amplification and/or mRNA overexpression are associated with higher levels of pAKT protein expression. However, more studies will be needed to further characterize if these changes could lead to a PI3K-AKT pathway activation that could justify the clinical use of PIK3CA and AKT inhibitors.
